Delving into the Latest Updates on Icanomab Gmbh with Synapse

Overview

Tags

Skin and Musculoskeletal Diseases

Neoplasms

Infectious Diseases

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Infectious Diseases	2
Endocrinology and Metabolic Disease	1
Hemic and Lymphatic Diseases	1
Immune System Diseases	1

Top 5 Drug Type	Count

Monoclonal antibody	3

Top 5 Target	Count

HER2(Receptor tyrosine-protein kinase erbB-2)	1
IL18RAP(interleukin 18 receptor accessory protein)	1
CD40(Tumor necrosis factor receptor superfamily member 5)	1

Author: Jiang, Liqiong ; Wegmann, Michael ; Dinarello, Charles A ; Webber, William S ; Amo-Aparicio, Jesus ; Li, Suzhao ; Orlicky, David J ; Falkesgaard Højen, Jesper ; Dinarello, Alberto ; Fischer, Stephan ; Parera, Daniel ; Lunding, Lars P ; Beckmann, Karsten ; Azam, Tania ; Nguyen, Tom T ; Pessara, Ulrich

IntroductionInterleukin-18 (IL-18), a pro-inflammatory cytokine belonging to the IL-1 Family, is a key mediator ofautoinflammatory diseases associated with the development of macrophage activation syndrome (MAS).High levels of IL-18 correlate with MAS and COVID-19 severity and mortality, particularly in COVID-19patients with MAS. As an inflammation inducer, IL-18 binds its receptor IL-1 Receptor 5 (IL-1R5), leadingto the recruitment of the co-receptor, IL-1 Receptor 7 (IL-1R7). This heterotrimeric complex subsequentlyinitiates downstream signaling, resulting in local and systemic inflammation.MethodsWe reported earlier the development of a novel humanized monoclonal anti-human IL-1R7 antibody whichspecifically blocks the activity of human IL-18 and its inflammatory signaling in human cell and wholeblood cultures. In the current study, we further explored the strategy of blocking IL-1R7 inhyperinflammation in vivo using animal models.ResultsWe first identified an anti-mouse IL-1R7 antibody that significantly suppressed mouse IL-18 andlipopolysaccharide (LPS)-induced IFNg production in mouse splenocyte and peritoneal cell cultures. Whenapplied in vivo, the antibody reduced Propionibacterium acnes and LPS-induced liver injury and protectedmice from tissue and systemic hyperinflammation. Importantly, anti-IL-1R7 significantly inhibited plasma,liver cell and spleen cell IFNg production. Also, anti-IL-1R7 downregulated plasma TNFa, IL-6, IL-1b,MIP-2 production and the production of the liver enzyme ALT. In parallel, anti-IL-1R7 suppressed LPSinducedinflammatory cell infiltration in lungs and inhibited the subsequent IFNg production andinflammation in mice when assessed using an acute lung injury model.DiscussionAltogether, our data suggest that blocking IL-1R7 represents a potential therapeutic strategy to specificallymodulate IL-18-mediated hyperinflammation, warranting further investigation of its clinical application intreating IL-18-mediated diseases, including MAS and COVID-19.

100 Deals associated with Icanomab Gmbh

Login to view more data

100 Translational Medicine associated with Icanomab Gmbh

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

IL-1R7 antagonist (Icanomab) ( IL18RAP )	Inflammation More	Preclinical
HER2newC apoptosis inducer (Icanomab) ( HER2 )	Early Stage Breast Carcinoma More	Preclinical
CD40 agonist (Icanomab) ( CD40 )	Neoplasms More	Preclinical